PT1242061E - Utilizacao de metabolitos bioactivos de gepirona para o fabrico de um medicamento para o tratamento de desordens psicologicas - Google Patents

Utilizacao de metabolitos bioactivos de gepirona para o fabrico de um medicamento para o tratamento de desordens psicologicas

Info

Publication number
PT1242061E
PT1242061E PT00986449T PT00986449T PT1242061E PT 1242061 E PT1242061 E PT 1242061E PT 00986449 T PT00986449 T PT 00986449T PT 00986449 T PT00986449 T PT 00986449T PT 1242061 E PT1242061 E PT 1242061E
Authority
PT
Portugal
Prior art keywords
psychological disorders
gepirona
drug
manufacture
treatment
Prior art date
Application number
PT00986449T
Other languages
English (en)
Inventor
Joseph P Yevich
Stephen J Kramer
Louis F Fabre
Original Assignee
Fabre Kramer Pharmaceuticals I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Kramer Pharmaceuticals I filed Critical Fabre Kramer Pharmaceuticals I
Publication of PT1242061E publication Critical patent/PT1242061E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT00986449T 1999-12-20 2000-12-18 Utilizacao de metabolitos bioactivos de gepirona para o fabrico de um medicamento para o tratamento de desordens psicologicas PT1242061E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17268499P 1999-12-20 1999-12-20
US09/709,741 US6534507B1 (en) 1999-12-20 2000-11-13 Methods for treating psychological disorders using bioactive metabolites of gepirone

Publications (1)

Publication Number Publication Date
PT1242061E true PT1242061E (pt) 2005-09-30

Family

ID=26868346

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00986449T PT1242061E (pt) 1999-12-20 2000-12-18 Utilizacao de metabolitos bioactivos de gepirona para o fabrico de um medicamento para o tratamento de desordens psicologicas

Country Status (20)

Country Link
US (1) US6534507B1 (pt)
EP (1) EP1242061B1 (pt)
JP (1) JP4236407B2 (pt)
KR (1) KR100602976B1 (pt)
CN (1) CN1411375A (pt)
AT (1) ATE294572T1 (pt)
AU (1) AU776409B2 (pt)
CA (1) CA2395458C (pt)
CZ (1) CZ300429B6 (pt)
DE (1) DE60019968T2 (pt)
ES (1) ES2241683T3 (pt)
HU (1) HU228963B1 (pt)
IL (2) IL150222A0 (pt)
MX (1) MXPA02006146A (pt)
NO (1) NO323304B1 (pt)
NZ (1) NZ519554A (pt)
PL (1) PL200378B1 (pt)
PT (1) PT1242061E (pt)
RU (1) RU2282448C2 (pt)
WO (1) WO2001045687A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295478A1 (en) * 2000-08-22 2002-03-04 Akzo Nobel N.V. Active metabolite of gepirone
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040000689A1 (en) * 2002-06-28 2004-01-01 Erh-Kun Lai Dual-bit MONOS/SONOS memory structure with non-continuous floating gate
PL374000A1 (en) 2002-08-12 2005-09-19 Bristol-Myers Squibb Company Improved process for hydroxyazapirones
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
TW200521125A (en) * 2003-11-18 2005-07-01 Bristol Myers Squibb Co Continuous process for producing hydroxyazapirones by oxidation
MX2007005368A (es) * 2004-11-05 2007-09-11 Fabre Kramer Holdings Inc Formulacion con liberacion prolongada de dosis alta de gepirona.
JP2011519953A (ja) * 2008-05-08 2011-07-14 ファーブル−クレイマー・ファーマシューティカルズ，インコーポレイテッド 注意欠陥障害および性機能不全の治療のための３−ヒドロキシジェピロン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
HU228963B1 (en) 2013-07-29
CZ20022137A3 (cs) 2003-03-12
NO20022954L (no) 2002-06-19
CA2395458A1 (en) 2001-06-28
NO20022954D0 (no) 2002-06-19
AU2268701A (en) 2001-07-03
ES2241683T3 (es) 2005-11-01
IL150222A0 (en) 2002-12-01
NZ519554A (en) 2005-01-28
PL200378B1 (pl) 2008-12-31
RU2282448C2 (ru) 2006-08-27
IL150222A (en) 2009-09-22
KR100602976B1 (ko) 2006-07-20
AU776409B2 (en) 2004-09-09
MXPA02006146A (es) 2004-08-23
JP2004500362A (ja) 2004-01-08
CZ300429B6 (cs) 2009-05-20
PL364936A1 (en) 2004-12-27
DE60019968D1 (de) 2005-06-09
JP4236407B2 (ja) 2009-03-11
KR20020082470A (ko) 2002-10-31
HUP0301831A2 (hu) 2003-09-29
US6534507B1 (en) 2003-03-18
DE60019968T2 (de) 2006-02-02
NO323304B1 (no) 2007-03-05
CN1411375A (zh) 2003-04-16
WO2001045687A3 (en) 2002-04-25
RU2002119400A (ru) 2004-01-27
WO2001045687A2 (en) 2001-06-28
ATE294572T1 (de) 2005-05-15
EP1242061A2 (en) 2002-09-25
EP1242061B1 (en) 2005-05-04
CA2395458C (en) 2009-05-12

Similar Documents

Publication Publication Date Title
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
AR027528A1 (es) Preparacion farmaceutica para el tratamiento de rinitis alergica y/o vasomotriz o conjuntivitis alergica, la utilizacion de dicha preparacion para laobtencion de medicamentos y el procedimiento para preparar dichos medicamentos
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
KR101853596B1 (ko) Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
PT1242061E (pt) Utilizacao de metabolitos bioactivos de gepirona para o fabrico de um medicamento para o tratamento de desordens psicologicas
EP1539136A4 (en) PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS
EP1256344A4 (en) REMEDIES FOR ENDOTHELIN-INDUCED DISEASES
PE20011004A1 (es) Composicion de liberacion controlada de un inhibidor de fosfodiesterasa 4
BR0209103A (pt) Omeprazol forma c, processo para preparação e uso do mesmo e formulação farmacêutica
KR960700696A (ko) 정맥성 질환 치료에 유용한 5-하이드록시트립타민-2 수용체 길항물질 조성물(5-ht₂receptor antagonist compositions useful in treating venous conditions)
RU2002118304A (ru) Способ подавления чувства страха
CA2364178A1 (en) N-benzenesulfonyl l-proline compounds as bradykinin antagonists
SE9902935D0 (sv) Pharmaceutical compositions
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
DE50312523D1 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
NO940274D0 (no) 2-(4-(-azolbutyl)-1-piperazinyl)-5-hydroksy-pyrimidinderivater, deres fremstilling og anvendelse som legemidler
DE3867042D1 (de) Pharmazeutische praeparate.
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
MY143571A (en) Eplerenone crystalline form
CA2590224A1 (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
RU2004126447A (ru) Лечение ревматоидного артрита